Rasuvo

Polymyositis, Uveitis, Prophylaxis against graft versus host disease + 27 more

Treatment

20 Active Studies for Rasuvo

What is Rasuvo

Methotrexate

The Generic name of this drug

Treatment Summary

Methotrexate is a medication used to reduce inflammation and stop cell division. It is commonly prescribed to treat certain types of arthritis, severe psoriasis, and certain forms of cancer, such as breast cancer and non-Hodgkin's lymphoma. This drug can cause side effects, so it is only used when other treatments have failed or if a patient is not able to tolerate them. Methotrexate was approved by the FDA in 1953.

Methotrexate

is the brand name

image of different drug pills on a surface

Rasuvo Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Methotrexate

Methotrexate

1953

137

Effectiveness

How Rasuvo Affects Patients

Methotrexate works by blocking enzymes that are involved in making new cells, resulting in reduced inflammation. It usually needs to be taken only once a week, but it is a powerful drug and should be taken carefully. Do not take methotrexate daily, as this could be dangerous.

How Rasuvo works in the body

Methotrexate prevents cells from dividing by blocking enzymes responsible for making nucleotides. In rheumatoid arthritis, this process also causes a buildup of adenosine in the body, which activates anti-inflammatory receptors to reduce inflammation.

When to interrupt dosage

The quantity of Rasuvo is contingent upon the diagnosed condition, including Uveitis, Polymyositis and nonleukemic meningeal cancer. The dosage is dependent upon the mode of delivery, as listed in the table below.

Condition

Dosage

Administration

Takayasu Arteritis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Medically induced abortion

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Acute Promyelocytic Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Soft Tissue Sarcoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chronic Graft Versus Host Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Arthritis, Juvenile

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Polymyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Uveitis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Chemotherapy

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Psoriasis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Leukemia

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma, Non-Hodgkin

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Dermatomyositis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Multiple Sclerosis

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Breast Cancer

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lymphoma

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Crohn's Disease

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Lupus

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Pregnancy, Ectopic

25.0 mg/mL, , 2.5 mg, 100.0 mg/mL, 25.0 mg, 7.5 mg, 10.0 mg, 15.0 mg, 20.0 mg, 50.0 mg, 150.0 mg/mL, 200.0 mg/mL, 250.0 mg/mL, 75.0 mg/mL, 125.0 mg/mL, 225.0 mg/mL, 175.0 mg/mL, 12.5 mg, 17.5 mg, 22.5 mg, 5.0 mg, 1000.0 mg, 2.5 mg/mL, 275.0 mg/mL, 300.0 mg/mL, 10.0 mg/mL, 20.0 mg/mL, 15.0 mg/mL, 2.0 mg/mL

, Injection, Injection - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Intra-arterial; Intramuscular; Intrathecal; Intravenous, Oral, Tablet - Oral, Tablet, Intra-arterial; Intramuscular; Intravenous, Injection, solution - Intra-arterial; Intramuscular; Intravenous, Intravenous, Intramuscular; Intrathecal; Intravenous, Powder, for solution - Intramuscular; Intrathecal; Intravenous, Liquid, Liquid - Intramuscular; Intrathecal; Intravenous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular, Powder, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Injection, solution - Subcutaneous, Subcutaneous, Tablet, film coated, Tablet, film coated - Oral, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Solution - Oral, Solution - Intravenous, Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Injection, solution - Intra-arterial; Intramuscular; Intrathecal; Iontophoresis, Solution, Solution - Intra-arterial; Intramuscular; Intravenous, Solution - Subcutaneous, Solution - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Liquid - Intravenous, Liquid - Intra-arterial; Intramuscular; Intrathecal; Intravenous, Powder, for solution, Intra-arterial; Intramuscular; Intrathecal; Intravenous; Intraventricular

Warnings

Rasuvo Contraindications

Condition

Risk Level

Notes

Non Neoplastic Condition

Do Not Combine

Severe Hypersensitivity Reactions

Do Not Combine

Methotrexate may interact with Pulse Frequency

There are 20 known major drug interactions with Rasuvo.

Common Rasuvo Drug Interactions

Drug Name

Risk Level

Description

2-Methoxyethanol

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 2-Methoxyethanol.

9-(N-methyl-L-isoleucine)-cyclosporin A

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.

Abetimus

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Abetimus.

Acteoside

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Acteoside.

Aldosterone

Major

The risk or severity of adverse effects can be increased when Methotrexate is combined with Aldosterone.

Rasuvo Toxicity & Overdose Risk

The lowest toxic dose of etoposide in rats and mice has been found to be 135mg/kg and 146mg/kg, respectively. Symptoms of overdose may include reduced white blood cell, platelet, and red blood cell counts, mouth and stomach sores, nausea and vomiting, ulcers in the digestive tract, and bleeding. In the event of an overdose, patients should be treated with glucarpidase and not receive leucovorin within 2 hours before or after glucarpidase.

image of a doctor in a lab doing drug, clinical research

Rasuvo Novel Uses: Which Conditions Have a Clinical Trial Featuring Rasuvo?

764 active studies are underway to investigate the potential of Rasuvo in providing therapeutic benefit for Uveitis, Small Cell Lung Cancer and Soft Tissue Sarcoma.

Condition

Clinical Trials

Trial Phases

Soft Tissue Sarcoma

51 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 4, Early Phase 1, Phase 3

Non-Hodgkin's Lymphoma

115 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Early Phase 1, Phase 4

Lupus

65 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4, Early Phase 1

Bladder Cancer

101 Actively Recruiting

Phase 2, Not Applicable, Phase 1, Phase 3, Early Phase 1

Acute Lymphoblastic Leukemia

120 Actively Recruiting

Phase 1, Phase 2, Phase 3, Not Applicable, Early Phase 1, Phase 4

Multiple Sclerosis

127 Actively Recruiting

Phase 3, Not Applicable, Phase 4, Phase 2, Phase 1, Early Phase 1

Rheumatoid Arthritis

55 Actively Recruiting

Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1

Hematopoietic stem cells

3 Actively Recruiting

Early Phase 1, Phase 1, Phase 2

Takayasu Arteritis

1 Actively Recruiting

Phase 2

Psoriasis

0 Actively Recruiting

Mycosis Fungoides

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

Crohn's Disease

54 Actively Recruiting

Phase 1, Phase 2, Not Applicable, Phase 3, Phase 4, Early Phase 1

Acute Promyelocytic Leukemia

0 Actively Recruiting

Breast Cancer

21 Actively Recruiting

Phase 2, Phase 1, Not Applicable

Sarcoma

0 Actively Recruiting

Lymphoma

4 Actively Recruiting

Phase 1, Phase 2

Gestational Trophoblastic Disease

0 Actively Recruiting

Pregnancy, Ectopic

0 Actively Recruiting

Polymyositis

3 Actively Recruiting

Phase 2, Phase 3

Rasuvo Reviews: What are patients saying about Rasuvo?

4

Patient Review

11/20/2015

Rasuvo for Rheumatoid Arthritis

Rasuvo helped me avoid the gastrointestinal issues that come with taking methotrexate pills. However, the injections are painful and often leave large bruises that take weeks to heal.

3.7

Patient Review

11/10/2015

Rasuvo for Rheumatoid Arthritis

Easy and painless to use. I started with 12.5mg but may go to 15 mg. Definitely avoids the gastrointestinal problems that come with oral methotrexate.

2.7

Patient Review

11/7/2016

Rasuvo for Rheumatoid Arthritis

I had been on the methotrexate pills for about 18 years. After a bout with cancer last year they didn't seem to be as effective. My rheumatologist prescribed Resuvo about 4 months ago. I have noticed an increase in side effects, severe gastrointestinal distress, nausea, diarrhea, headaches, dizziness, confusion and blood in urine. I will not continue taking this medication

2.7

Patient Review

9/26/2015

Rasuvo for Rheumatoid Arthritis

Injecting this medication was not as easy or painless as the Otrexup injector.

1.3

Patient Review

11/3/2014

Rasuvo for Rheumatoid Arthritis

I've tried both Otrexup and Rasuvo. I definitely had a better experience with Otrexup-- it was easier to use and didn't hurt like Rasuvo did.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about rasuvo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Rasuvo injection?

"-

Rasuvo is a medication used to treat leukemia, certain types of cancer, severe psoriasis, and rheumatoid arthritis. It is also used to treat active polyarticular-course juvenile rheumatoid arthritis in children."

Answered by AI

Is Rasuvo a chemo drug?

"Methotrexate goes by various trade names, including Otrexup, Rasuvo, and Rheumatrex. It is an anti-cancer drug."

Answered by AI

Is Rasuvo the same as methotrexate?

"Rasuvo is a single-dose auto-injector containing the prescription medicine methotrexate."

Answered by AI

What is Rasuvo used for?

"Methotrexate, marketed as Rasuvo, is a drug used to manage severe cases of rheumatoid arthritis and juvenile idiopathic arthritis. It is intended for patients who have not responded well to non-steroidal anti-inflammatory drugs or who are unable to tolerate them."

Answered by AI

Clinical Trials for Rasuvo

Image of The University of British Columbia in Vancouver, Canada.

Treatment for Crohn's Disease

9 - 17
All Sexes
Vancouver, Canada

Children with Crohn's disease (CD), a type of Inflammatory Bowel Disease (IBD), often face serious health challenges, including poor growth, frequent hospital stays, and long-term medication use. Although biologic drugs like infliximab, an anti-TNFα (Tumor necrosis factor α) medication, have improved treatment, they don't work for everyone: many children still experience symptoms or disease flare-ups. Nutritional therapies, especially the Crohn's Disease Exclusion Diet (CDED), may help improve treatment outcomes. This study will assess whether starting CDED at the same time as infliximab leads to better responses to treatment. The goal of this study is to improve how well children respond to therapy, reduce drug exposure, and support better long-term health.

Waitlist Available
Has No Placebo

The University of British Columbia

Kevan Jacobson, MBBCh, FRCP, FRCPC, AGAF, CAGF

Image of MUHC - Montreal General Hospital in Montreal, Canada.

Ustekinumab for Crohn's Disease and Ulcerative Colitis

18+
All Sexes
Montreal, Canada

The goal of this clinical trial is to evaluate whether disease remission can be maintained when biologic therapy is reduced in patients with Crohn"s disease (CD) and ulcerative colitis (UC) taking ustekinumab (UST). The main question it aims to answer is: Can we de-escalate UST subcutaneous dose either from every 4 weeks (Q4) to every 8 weeks (Q8) or every 8 weeks (Q8) to every 12 weeks (Q12) in CD or UC patients in deep remission without loosing their response? Researchers will follow UST blood levels, inflammation markers and intestinal mucosa integrity and to see if UST dose can be reduced while maintaining clinical remission. Participants will: Change UST dosing from Q4 to Q8 or from Q8 to Q12. Visit the clinic once every 12 weeks for checkups and tests.

Phase 4
Recruiting

MUHC - Montreal General Hospital

Janssen Inc.

Have you considered Rasuvo clinical trials?

We made a collection of clinical trials featuring Rasuvo, we think they might fit your search criteria.
Go to Trials
Image of Washington University School of Medicine in St Louis, United States.

Supplemental Imaging for Breast Cancer

25 - 55
Female
St Louis, MO

Recent research has shown that, among women with extremely dense breasts and normal results on mammogram, magnetic resonance imaging (MRI) use has significantly reduced the occurrence of breast cancer that is diagnosed during the time between two regular screening mammograms (also known as interval cancers). The investigators have developed and validated an approach to use the whole mammogram image, develop a mammogram risk score (MRS), and calibrate this to the SEER breast cancer incidence rates for US women. This model (Prognosia Breast) generates an absolute 5-year risk of breast cancer and classifies approximately 5.7% of the population as high risk using the ASCO 3% cut point as used for endocrine therapy to reduce risk. Follow-up generates an incidence of 25.2 cases per 1,000 women per year.

Waitlist Available
Has No Placebo

Washington University School of Medicine

Tabassum Ahmad, M.D.

Have you considered Rasuvo clinical trials?

We made a collection of clinical trials featuring Rasuvo, we think they might fit your search criteria.
Go to Trials
Image of Investigative Site in Beverly Hills, United States.

VENT-03 for Lupus

18 - 70
All Sexes
Beverly Hills, CA

The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE). Another goal is to learn about the safety of VENT-03 and how it is processed by the body. The main questions it aims to answer are: * Does VENT-03 affect the activity and severity of CLE? * What side effects do participants have when taking VENT-03? Researchers will compare VENT-03 to a placebo (a look-alike substance that contains no drug) to see if VENT-03 works to treat patients with CLE. Participants will: * Take VENT-3 or a placebo every day for 4 weeks, then all participants will switch to VENT-03 for another 8 weeks; * Visit the clinic once a month for checkups and tests.

Phase 2
Recruiting

Investigative Site (+9 Sites)

Ventus Therapeutics U.S., Inc.

Image of The University of Arizona Cancer Center in Tucson, United States.

DLI-X for Leukemia

Any Age
All Sexes
Tucson, AZ

The primary objective of this proposal is to conduct the first-in-human randomized clinical trial evaluating prophylactic DLI-X (pro-DLI-X) for relapse prevention following matched sibling donor (MSD) or haploidentical (haplo) hematopoietic cell transplantation (HCT) in patients with hematologic malignancies. Additionally, the study aims to assess the safety and efficacy of therapeutic DLI-X (t-DLI-X) compared to t-DLI alone in patients with minimal residual disease (MRD+) or overt relapse post-alloHCT. For patients with CD19-positive lymphoid malignancies, the study will incorporate blinatumomab, while those with myeloid or CD19-negative lymphoid malignancies will receive t-DLI-X or t-DLI alone. We hypothesize that both pro-DLI-X and t-DLI-X, with or without blinatumomab, will demonstrate safety and superior efficacy by enhancing graft-versus-leukemia (GvL) effects mediated by natural killer (NK) cells, γδ T cells, and CD8+ T cells, while maintaining manageable and treatment-responsive graft-versus-host disease (GvHD).

Phase 1
Waitlist Available

The University of Arizona Cancer Center

Emmanuel Katsanis, MD

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada

People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.

Phase 4
Waitlist Available

Sunnybrook Health Sciences Centre (+4 Sites)

Have you considered Rasuvo clinical trials?

We made a collection of clinical trials featuring Rasuvo, we think they might fit your search criteria.
Go to Trials